Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Charles River Laboratories International's quarterly other long-term liabilities
increased
from Dec. 2025 (MXN2,490 Mil) to Mar. 2026 (MXN9,208 Mil) but then
declined
from Mar. 2026 (MXN9,208 Mil) to Jun. 2026 (MXN7,023 Mil).
Charles River Laboratories International's annual other long-term liabilities
increased
from Dec. 2023 (MXN3,788 Mil) to Dec. 2024 (MXN4,071 Mil) but then
declined
from Dec. 2024 (MXN4,071 Mil) to Dec. 2025 (MXN2,490 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International Other Long-Term Liabilities Chart
Charles River Laboratories International Annual Data
Charles River Laboratories International Other Long-Term Liabilities Calculation
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
What does a Other Long-Term Liabilities of MXN7,023 Mil mean?
Charles River Laboratories International (MEX:CRL) has a Other Long-Term Liabilities of MXN7,023 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's Other Long-Term Liabilities too high?
Charles River Laboratories International's current Other Long-Term Liabilities is MXN7,023 Mil. Overall, Charles River Laboratories International has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Other Long-Term Liabilities compare to RVTY and ICLR?
Charles River Laboratories International's Other Long-Term Liabilities of MXN7,023 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Other Long-Term Liabilities is MXN7,023 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (MEX:CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,782.12, compared to a current price of MXN4,720.00 — trading 69.7% above its estimated fair value. The current Other Long-Term Liabilities is MXN7,023 Mil. Charles River Laboratories International's overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Charles River Laboratories International (MEX:CRL), the current Other Long-Term Liabilities is MXN7,023 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (MEX:CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of MXN4,720.00 is trading 69.7% above its estimated GF Value™ of MXN2,782.12.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for MEX:CRL:
Other Long-Term Liabilities: MXN7,023 Mil
GF Value™: MXN2,782.12 vs. price of MXN4,720.00 (69.7% above fair value)
No single metric tells the full story. See the MEX:CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
51GF Score
Get the complete analysis for MEX:CRL
Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CRL has been successfully added to your 
